Cargando…

A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2

In a phase 1/2, open-label dose escalation trial, we delivered rAAVrh74.MCK.GALGT2 (also B4GALNT2) bilaterally to the legs of two boys with Duchenne muscular dystrophy using intravascular limb infusion. Subject 1 (age 8.9 years at dosing) received 2.5 × 10(13) vector genome (vg)/kg per leg (5 × 10(1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flanigan, Kevin M., Vetter, Tatyana A., Simmons, Tabatha R., Iammarino, Megan, Frair, Emma C., Rinaldi, Federica, Chicoine, Louis G., Harris, Johan, Cheatham, John P., Cheatham, Sharon L., Boe, Brian, Waldrop, Megan A., Zygmunt, Deborah A., Packer, Davin, Martin, Paul T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483573/ https://www.ncbi.nlm.nih.gov/pubmed/36186954 http://dx.doi.org/10.1016/j.omtm.2022.08.009

Ejemplares similares

An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.GALGT2 to Leg Skeletal Muscles in the Rhesus Macaque
por: Xu, Rui, et al.
Publicado: (2018)

rAAVrh74.MCK.GALGT2 Demonstrates Safety and Widespread Muscle Glycosylation after Intravenous Delivery in C57BL/6J Mice
por: Zygmunt, Deborah A., et al.
Publicado: (2019)

Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
por: Martin, Paul T., et al.
Publicado: (2021)

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial
por: Mendell, Jerry R., et al.
Publicado: (2020)

Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy
por: Goedeker, Natalie L., et al.
Publicado: (2023)

Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Potter, Rachael A., et al.
Publicado: (2021)

Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy
por: Willcocks, Rebecca J., et al.
Publicado: (2021)

Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1
por: Sahenk, Zarife, et al.
Publicado: (2021)

Pre Clinical Assessment of AAVrh74.MCK.GNE Viral Vector Therapeutic Potential: Robust Activity Despite Lack of Consistent Animal Model for GNE Myopathy
por: Mitrani-Rosenbaum, Stella, et al.
Publicado: (2022)

Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates
por: Borel, Florie, et al.
Publicado: (2016)

Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy
por: Shoti, Jakob, et al.
Publicado: (2023)

Therapeutic efficacy of rscAAVrh74.miniCMV.LIPA gene therapy in a mouse model of lysosomal acid lipase deficiency
por: Lam, Patricia, et al.
Publicado: (2022)

A role for Galgt1 in skeletal muscle regeneration
por: Singhal, Neha, et al.
Publicado: (2015)

Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping
por: Gushchina, Liubov V., et al.
Publicado: (2021)

The Viral Chemokine MCK-2 of Murine Cytomegalovirus Promotes Infection as Part of a gH/gL/MCK-2 Complex
por: Wagner, Felicia M., et al.
Publicado: (2013)

Mck1 kinase is a new player in the DNA damage checkpoint pathway
por: Sanvisens Delgado, Nerea, et al.
Publicado: (2019)

Automated immunofluorescence analysis for sensitive and precise dystrophin quantification in muscle biopsies
por: Vetter, Tatyana A., et al.
Publicado: (2021)

Correction: Mck1 kinase is a new player in the DNA damage checkpoint pathway
Publicado: (2020)

The budding yeast GSK-3 homologue Mck1 is an essential component of the spindle position checkpoint
por: Rathi, Siddhi, et al.
Publicado: (2022)

Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
por: Wein, Nicolas, et al.
Publicado: (2022)

The Yeast GSK-3 Homologue Mck1 Is a Key Controller of Quiescence Entry and Chronological Lifespan
por: Quan, Zhenzhen, et al.
Publicado: (2015)

The MAPKKK CgMck1 Is Required for Cell Wall Integrity, Appressorium Development, and Pathogenicity in Colletotrichum gloeosporioides
por: Fang, Yu-Lan, et al.
Publicado: (2018)

Mck1 defines a key S-phase checkpoint effector in response to various degrees of replication threats
por: Li, Xiaoli, et al.
Publicado: (2019)

Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy
por: Gushchina, Liubov V., et al.
Publicado: (2022)

OUTCOME MEASURES: EP.325 Remote testing: is it worth the effort? Feasibility in the clinical and research setting
por: Powers, B., et al.
Publicado: (2021)

Persistent Expression of Biologically Active Anti-HER2 Antibody by AAVrh.10-mediated Gene Transfer
por: Wang, Guoqing, et al.
Publicado: (2010)

Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?
por: Rafi, Mohammad A, et al.
Publicado: (2021)

Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping
por: Simmons, Tabatha R., et al.
Publicado: (2021)

A Yeast GSK-3 Kinase Mck1 Promotes Cdc6 Degradation to Inhibit DNA Re-Replication
por: Ikui, Amy E., et al.
Publicado: (2012)

Chronological Lifespan in Yeast Is Dependent on the Accumulation of Storage Carbohydrates Mediated by Yak1, Mck1 and Rim15 Kinases
por: Cao, Lu, et al.
Publicado: (2016)

Mouse Cytomegalovirus Differentially Exploits Cell Surface Glycosaminoglycans in a Cell Type-Dependent and MCK-2-Independent Manner
por: Pontejo, Sergio M, et al.
Publicado: (2019)

Long-term muscle-specific overexpression of DOK7 in mice using AAV9-tMCK-DOK7
por: Huang, Yu-Ting, et al.
Publicado: (2023)

Diagnostic Stewardship of Respiratory Pathogen Panel Utilization
por: Kressel, Amy, et al.
Publicado: (2021)

Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model
por: Gushchina, Liubov V., et al.
Publicado: (2023)

Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy
por: Homs, Judit, et al.
Publicado: (2014)

Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice
por: Tanguy, Yannick, et al.
Publicado: (2015)

Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?
por: Bey, Karim, et al.
Publicado: (2020)

Validation of Anti-Adeno Associated Virus Serotype rh10 (AAVrh.10) Total and Neutralizing Antibody Immunogenicity Assays
por: Butala-Flores, Elizabeth, et al.
Publicado: (2023)

MCK1 is a novel regulator of myo-inositol phosphate synthase (MIPS) that is required for inhibition of inositol synthesis by the mood stabilizer valproate
por: Yu, Wenxi, et al.
Publicado: (2017)

AAVrh.10-mediated Genetic Delivery of Bevacizumab to the Pleura to Provide Local Anti-VEGF to Suppress Growth of Metastatic Lung Tumors
por: Watanabe, Masaki, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5nvoehvtt5ohq59u60uc1m0o6f